Pulmatrix Revenue and Competitors
Estimated Revenue & Valuation
- Pulmatrix's estimated annual revenue is currently $7.5M per year.
- Pulmatrix's estimated revenue per employee is $234,375
- Pulmatrix's total funding is $148.2M.
Employee Data
- Pulmatrix has 32 Employees.
- Pulmatrix grew their employee count by -20% last year.
Pulmatrix's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP, CMC and Pharmaceutical Development | Reveal Email/Phone |
3 | Associate Director | Reveal Email/Phone |
4 | Director, Analytical Development | Reveal Email/Phone |
5 | Associate Director Quality Assurance | Reveal Email/Phone |
6 | Director Intellectual Property and Contracts | Reveal Email/Phone |
7 | Manager, Particle Engineering | Reveal Email/Phone |
8 | Quality Control Supervisor | Reveal Email/Phone |
9 | Senior Research Associate | Reveal Email/Phone |
10 | Analyst | Reveal Email/Phone |
Pulmatrix Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Pulmatrix?
Pulmatrix was founded in 2003 and is based on the ground breaking work of Harvard University Professor David Edwards. Mr. Gabrielson and Dr. Edwards co-founded the company with MIT Professors Bob Langer and Alexander Klibanov. Pulmatrix is financed by Polaris Venture Partners and 5AM Ventures. Pulmatrix’s lead therapeutic program should enter a Phase I clinical study this quarter.
keywords:Biotechnology
$148.2M
Total Funding
32
Number of Employees
$7.5M
Revenue (est)
-20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Pulmatrix News
Zacks Investment Research downgraded shares of Pulmatrix from a buy rating to a hold rating in a report on Thursday, January 13th. HC...
Hedge funds and other institutional investors own 20.09% of the company's stock. Get Pulmatrix alerts: A number of research analysts recently...
Zacks Investment Research cut shares of Pulmatrix from a buy rating to a hold rating in a research report on Thursday, January 13th. Get...
LEXINGTON, Mass., Aug. 10, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today reports its second quarter 202 ...
LEXINGTON, Mass., July 27, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced the appointment of A ...
Other Companies in Lexington
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.8M | 32 | 3% | N/A |
#2 | $8.4M | 32 | -9% | N/A |
#3 | $4.5M | 32 | -48% | N/A |
#4 | $6.2M | 32 | 3% | N/A |
#5 | $1.7M | 32 | 33% | N/A |